Christian Furlan Freguia
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$7.2MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $7.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 3, 2026 | NIH | SBIR Phase II A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's Disease | $1.0M | Rise Therapeutics, LLC |
| Jul 16, 2025 | NIH | SBIR Phase II A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis | $828K | Rise Therapeutics, LLC |
| Aug 21, 2024 | NIH | SBIR Phase II R-5280, A Novel Modified Superior Resistant Starch Therapy for Type 1 Diabetes | $996K | Rise Therapeutics, LLC |
| Jul 22, 2024 | NIH | SBIR Phase II A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis | $956K | Rise Therapeutics, LLC |
| Dec 7, 2023 | NIH | SBIR Phase II A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS) | $984K | Rise Therapeutics, LLC |
| Jun 22, 2023 | NIH | SBIR Phase II A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes | $984K | Rise Therapeutics, LLC |
| Apr 24, 2023 | NIH | SBIR Phase II A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis | $306K | Rise Therapeutics, LLC |
| Sep 1, 2022 | NIH | SBIR Phase II A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes | $78K | Rise Therapeutics, LLC |
| Jun 24, 2022 | NIH | SBIR Phase II A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes | $1.0M | Rise Therapeutics, LLC |
Peer ranks
Federal funding#136
Awards as PI#151
Patents#273
Companies
- Rise Therapeutics, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.